Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...

European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, ...

The ex-CytoDyn chief exec must also forfeit more than $4.4 million—approximately the amount he profited from the scheme—and ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

A federal grand jury in Rhode Island has charged two former top executives of Colorado-based medical device company Zynex Inc. | A federal grand jury in Rhode Island has charged two former top ...

Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...